You are here: Industry Insights > NASH

News List

Bridging Study in China Completed for NASH Drug Candidate ASC40 prnasia
July 20, 2020
Ascletis Pharma Inc. (HKEX code: 1672) announces today that a single-dose, pharmacokinetic bridging study of non-alcoholic steatohepatitis (NASH) drug candidate ASC40 (TVB-2640) in 34 Chinese subjects has been completed and data indicates that key pharma
Sagimet Announces Positive Results in NASH Trial of FASN Inhibitor TVB-2640 americanpharmaceuticalreview
June 29, 2020
Sagimet Biosciences announced positive results from FASCINATE-1, the Phase 2 clinical trial of its oral, once-daily FASN inhibitor TVB-2640, the company's lead product candidate that is currently being evaluated as a potential treatment for ...
DURECT Announces Positive Topline Data from NASH Study americanpharmaceuticalreview
June 02, 2020
DURECT Corporation announced positive topline results from its Phase 1b clinical study of orally administered DUR-928 in nonalcoholic steatohepatitis (NASH) patients.
NASH: Seizing The USD40-Billion NASH Drug Market PharmaSources/Caicai
March 19, 2020
The global NASH drug market will reach USD40 billion by 2025. Such a huge market is in urgent need of blockbusters.
NGM Bio Announces Positive Preliminary Topline Liver Histology of Aldafermin in NASH Patients americanpharmaceuticalreview
March 10, 2020
NGM Biopharmaceuticals announced positive preliminary topline results from the 24-week double-blind, randomized, placebo-controlled cohort (Cohort 4) of an adaptive Phase 2 study evaluating the efficacy ...
Zydus’ saroglitazar becomes first NASH drug approved globally pharmaceutical-technology
March 09, 2020
The Drug Controller General of India has approved Zydus’ saroglitazar for non-cirrhotic non-alcoholic steatohepatitis (NASH).
Ascletis' IND Filing for Its Non-alcoholic Steatohepatitis (NASH) Drug Accepted by NMPA prnasia
February 18, 2020
Ascletis Pharma Inc. (HKEX code: 1672) announces today the application for in-house developed Category 1 Drug ASC41 for clinical trials of NASH indication has been accepted by China's National Medical Products Administration (NMPA).
Akero Expands NASH Trial to Include Cohort of Cirrhotic Patients americanpharmaceuticalreview
January 19, 2020
Akero Therapeutics announced the ongoing Phase 2a BALANCED study of AKR-001 is being expanded to include an additional cohort of subjects with non-alcoholic steatohepatitis (NASH) who have compensated cirrhosis (F4), Child-Pugh Class A.
Nonalcoholic Steatohepatitis Will Pose Clinical, Economic Burden drugs
January 15, 2020
Nonalcoholic steatohepatitis (NASH) is expected to pose a significant clinical and economic burden during the next 20 years for U.S. patients with type 2 diabetes mellitus (T2DM), according to a study published online January in Diabetes Care.
First investigational drug therapy for liver disease NASH awaiting FDA approval worldpharmanews
December 09, 2019
Patients with nonalcoholic steatohepatitis (NASH), a chronic liver disease and a leading cause for liver transplantation in the U.S., currently lack an approved drug therapy ...

Previous page 1 2 3 4 5 6 7 8 9 10 11 Next page